BioCentury
ARTICLE | Company News

XTL and Hybrigenics in HCV deal

September 5, 2000 7:00 AM UTC

XTL (Rehovot, Israel) and Hybrigenics (Paris, France) will develop therapeutics to treat hepatitis C virus (HCV) infection. Hybrigenics will use its PIMRider proteomics and bioinformatics platform to ...